Biote Q4 revenue slightly beats estimates

biote

11/03/2026 20:21

Overview

U.S. hormone therapy provider's Q4 revenue fell 6.9% but slightly beat analyst expectations

Adjusted EBITDA for Q4 declined 22.8% from the prior year

Outlook

Biote sees 2026 revenue above $190 mln

Company expects 2026 adjusted EBITDA above $38 mln

Procedure revenue expected to decrease in H1 2026, return to growth in H2 2026

Result Drivers

PROCEDURE REVENUE DECLINE - Q4 procedure revenue fell 13%, which the company said was partially offset by growth in dietary supplements

INVENTORY RECALL CHARGE - Gross margin was reduced by a $1.3 mln inventory charge related to a voluntary recall of hormone pellets

Company press release: ID:nBwzlhsYa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Beat*
$46.4 mln
$46.19 mln (5 Analysts)
Q4 Adjusted EBITDA
$11.7 mln
Q4 Gross Margin
68%
Q4 Adjusted EBITDA Margin
25.2%
Q4 Operating Income
$6.8 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the professional information services peer group is "buy"

Wall Street's median 12-month price target for Biote Corp is $4.75, about 179.4% above its March 10 closing price of $1.70

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)